42
Participants
Start Date
November 5, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
mosunetuzumab
1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
glofitamab
2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
obinutuzumab
1000 mg IV on Cycle 1 Day 1.
RECRUITING
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RECRUITING
University of Nebraska Medical Center, Omaha
Collaborators (1)
Genentech, Inc.
INDUSTRY
Abramson Cancer Center at Penn Medicine
OTHER